Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma

Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma

Abstract Background Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy. As a second-generation alkylating agent, TMZ provides superior oral bio-availability. However, limited response rate (less than 50%) and high incidence of drug resistance seriously restricts TMZ’s appli...

Full description

Bibliographic Details
Main Authors: Xiaoying Hou, Hongzhi Du, Yufei Deng, Haiping Wang, Jinmi Liu, Jialu Qiao, Wei Liu, Xiji Shu, Binlian Sun, Yuchen Liu
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Journal of Translational Medicine
Subjects:
Temozolomide
Fecal microbiome
Functional Metabolomics
Individualized efficacy
Glioma
Online Access:https://doi.org/10.1186/s12967-023-04042-5

Internet

https://doi.org/10.1186/s12967-023-04042-5

Similar Items